Mezigdomide: Clinical Trials

2 trials of Mezigdomide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 recruiting. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Active not recruiting 1, Recruiting 1

Follow Mezigdomide: new trials by email Literature Review of Mezigdomide trials Research Report on Mezigdomide

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Mezigdomide, Carfilzomib, Dexamethasone - Relapsed or Refractory Multiple Myeloma
Phase 3Active not recruitingBristol-Myers Squibb6062023-01-102026-09-24
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
mezigdomide, Pomalidomide, Bortezomib - Relapsed or Refractory Multiple Myeloma
Phase 3RecruitingCelgene8102022-09-202026-10-30

Conditions studied

Multiple Myeloma (2)  ·  Recurrence (2)

Sponsors

Bristol-Myers Squibb (1)  ·  Celgene (1)

Countries

Argentina (2)  ·  Australia (2)  ·  Austria (2)  ·  Brazil (2)  ·  Canada (2)  ·  China (2)  ·  Germany (2)  ·  Greece (2)  ·  India (2)  ·  Israel (2)  ·  Italy (2)  ·  Japan (2)  ·  Puerto Rico (2)  ·  Romania (2)  ·  South Korea (2)

Results publications

PMID 42289183

NIH funding

2023 (1)